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KAJIAN PENDOKKAN DAN SIMULASI DINAMIK MOLEKUL 
TERHADAP INTERAKSI INSULIN-β-SIKLODEKSTRIN  
 
ABSTRAK 
 Interaksi protein-ligan memainkan peranan penting dalam menyediakan 
produk farmaseutikal yang baharu. Kajian ini merupakan usaha untuk memahami 
struktur dan dinamik kompleks insulin-siklodekstrin sebagai formula insulin oral 
yang baharu. Pendokkan dan simulasi dinamik molekul telah dijalankan untuk 
mengkaji interaksi antara monomer insulin dan dimer insulin terhadap β-
siklodekstrins (β-CDs). Kajian pendokkan molekul berganda telah dijalankan 
menggunakan program Autodock v4.2 untuk menentukan bilangan β-CD yang boleh 
terikat pada tapak ikatan insulin selain menentukan konformasi insulin-β-CD yang 
paling stabil. Pendokkan molekul dengan 100 struktur rawak menggunakan 
konformasi awal nisbah monomer insulin kepada β-CD dan dimer insulin-β-CD 1:1 
telah dijalankan dan daripada struktur pendokkan terakhir, β-CD telah ditambah dan 
proses diulangi sehingga peningkatan tenaga didapati. Keputusan pendokkan 
molekul menunjukkan maksimum empat molekul β-CD boleh terikat kepada struktur 
insulin dan nisbah insulin kepada β-CD 1:3 menghasilkan tenaga bebas pengikatan 
terendah. Selain pembentukan ikatan hidrogen, keputusan pendokkan menunjukkan 
bahawa interaksi hidrofobik memainkan peranan penting dalam menentukan 
kestabilan kompleks insulin-β-CD. Simulasi dinamik molekul 100 ns seterusnya 
dijalankan untuk membandingkan keputusan yang terhasil daripada kajian 
pendokkan molekul. Analisa daripada simulasi dinamik molekul mengesahkan 
kestabilan pada kompleks  dimer insulin-β-CD 1:3 dengan nilai sisihan punca min 
xviii 
 
kuasa dua (RMSD) sebanyak 0.40 ± 0.02 nm selepas 38 ns menunjukkan perbezaan 
yang sangat besar berbanding sistem insulin bebas. Peningkatan nilai luas permukaan 
boleh dicapai pelarut (SASA) pada kompleks 1:3 insulin dimer-β-CD selaras dengan 
interaksi hidrofobik dalam sistem kompleks, oleh yang demikian menambahkan 
lipatan dan kestabilan insulin. Profil pergolakan punca min kuasa dua (RMSF) 
menunjukkan pengurangan fleksibiliti terhadap residu asid amino dalam insulin 
dimer dalam sistem kompleks berbanding sistem insulin bebas. Seterusnya, struktur 
dan dinamik asid amino pada setiap tapak ikatan dan kesannya terhadap β-CD turut 
dikaji. Keputusan menunjukkan β-CD terikat stabil pada setiap tapak ikatan pada 
insulin dimer dengan pergerakan terhad sekitar nilai minima. Selain itu, asid-asid 
amino berkutub seperti sistina (Cys62), serina (Ser63) dan glutamina (Gln66) terlibat 
dengan kekerapan tertinggi dalam pembentukkan ikatan hidrogen masing-masing 
dengan nilai peratusan 74.0 %, 54.3 % dan 51.9 %. Keputusan teori ini menunjukkan 
kewujudan interaksi penting antara insulin dan β-CD yang mana boleh 
menyumbangkan maklumat penting terhadap formulasi insulin. 
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DOCKING AND MOLECULAR DYNAMICS SIMULATION STUDIES OF 
INSULIN-β-CYCLODEXTRIN INTERACTIONS 
 
ABSTRACT 
 Protein-ligand interactions play an essential role in the design of new 
pharmaceutical products. This study attempts to understand the theoretical basis on 
the structure and dynamics of insulin-cyclodextrin complex for new oral insulin 
formulation. Docking and molecular dynamics simulations were performed to 
explore the interactions between insulin monomer and insulin dimer with β-
cyclodextrins (β-CDs). A multiple molecular docking study was performed using the 
Autodock v4.2 program to determine the number of β-CD that can adhere to the 
binding sites of insulin as well as to determine the most stable conformations of 
insulin to β-CDs. A 100 random structure docking using 1:1 insulin monomer-β-CD 
and insulin dimer-β-CD ratio were conducted and from the final docked structure, 
additional β-CDs were added and the process were repeated until the energy increase. 
Molecular docking results revealed that a maximum of four β-CDs can bind to an 
insulin structure with the 1:3 insulin-β-CD ratios having the lowest binding free 
energy. A 100 ns molecular dynamics simulation was then conducted to verify the 
results obtained by molecular docking. In addition to the hydrogen bonding 
formations, the docked conformations showed that hydrophobic interactions played a 
crucial role in insulin-β-CD conformational stability. The analysis of the molecular 
dynamics simulation confirmed the stability of the 1:3 insulin dimer-β-CD complex 
system with root mean square deviation (RMSD) values of 0.40 ± 0.02 nm after 38 
ns and showed a large difference compared to the free insulin system. The increase 
xx 
 
of solvent accessible surface area (SASA) values in 1:3 insulin dimer-β-CD complex 
is consistent with the hydrophobic interactions in the formation complex, therefore 
increasing the insulin folding and stability. The root mean square fluctuation (RMSF) 
profiles of the 1:3 insulin dimer in complex system also showed a reduced flexibility 
of amino acid residues of insulin dimer in complex compared to free insulin. 
Furthermore, the structure and dynamics of amino acids in insulin at each binding 
site along with its effect on β-CDs were further investigated. The results indicated 
that the β-CDs were stably bound to each binding site of the insulin dimer with 
limited movement around the mean value. In addition to this, the polar amino acids 
of cystein (Cys62), serine (Ser63) and glutamine (Gln66) were involved with the 
highest occupancy of hydrogen bonds with 74.0 %, 54.3 % and 51.9 %, respectively. 
The theoretical results indicated the presence of significant interactions between 
insulin and β-CD, which could provide useful insights into an oral insulin 
formulation. 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
During the last decade, approximately 300 million people worldwide were 
affected by Diabetes Mellitus (DM) (Williams et al., 2002) with the Asian countries 
representing more than 60% of that diabetic population (Ramachandran et al., 2012). 
DM is defined as an endocrine disease which is related to the disorders of 
carbohydrate metabolism carried about by deficiency in insulin secretion, insulin 
resistance or both (Belchetz & Hammond, 2004). There are three types of DM: Type 
1, Type 2 and the gestational diabetes that happens only to pregnant women (Carino 
& Mathiowitz, 1999). 
Type 1 diabetes occurs due to the destruction of pancreatic beta islet cells. 
This leads to insulin deficiency and predisposes individuals to diabetic ketoacidosis 
(Mohan, 2005). This type of diabetes usually happens in childhood and requires 
patients to inject themselves with insulin to reduce glucose levels. Type 2 diabetes 
occurs in adults and is caused by the inability of the pancreas to produce insulin and 
resist peripheral insulin (Gale, 2001; Skyler, 2004). The development of factors 
leading to Type 2 diabetes are due to genetic inheritance, beta cell dysfunction 
(Mohan, 2005), the environment of beta cells (Pittas & Greenberg, 2003), insulin 
resistance (Saltiel, 2001), obesity (Kahn & Flier, 2000), the role of fatty acids which 
inhibit insulin signaling (Shulman, 2000), the role of adipokines (Saltiel, 2001), 
improper nutrition (Steyn  et al., 2004) and low physical activity in patients (Caro et 
al., 1989). 
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In order to prevent these complications, people with Type 2 diabetes are 
usually treated with dietary measures, oral medicines and exercises. Insulin 
injections are compulsory for Type 1 diabetic patients, however, some Type 2 
diabetic patients need insulin injections to control the glucose level in their 
blood.  Due to the fast development in biotechnology over the past few decades, 
variants of insulin from different sources were produced. These include rapid (Shafie 
et al., 2014), short (Siebenhofer et al., 2006), intermediate (Norrman et al., 2007), 
long (Luzio et al., 2013) and ultralong-acting (Wang et al., 2012) insulin. These 
insulin variants must be administered via injections and may result in one or more 
disadvantages to patients such as needle phobia, skin bulges, allergic reactions, 
common infections and tenseness of long-term usage of injection insulin (Kennedy, 
1991; Khafagy et al., 2007). Furthermore, the treatment of injected insulin can lead 
to peripheral hyperinsulinemia, which is due to the directly insulin transfer into 
general circulation in human body. Hyperinsulinemia is diabetes‘s side effect which 
is linked to cancer, hypoglycemia, peripheral hypertension and the development of 
atherosclerosis (Nordestgard, 1997). The clinical trials by Pamnani (2008) shows that 
a significant percentage of patients failed to achieve lasting glycemic control due to 
the patients‘ noncompliance with injectable insulin treatment. Due to this problem, 
current research on insulin has focused on the development of an alternative delivery 
method to injection. These include buccal/sublingual (Portero et al., 2007), nasal (Yu 
et al., 2004), pulmonary (Stephen et al., 2000), ocular (Owens, 2002), transdermal 
(Rastogi et al., 2010) as well as oral (Zhang et al., 2013). 
Oral insulin administration is the most effective and possible technique to 
be used compared to the other routes. This is because insulin will be directly 
transferred to the liver and consequently avoids the peripheral hyperinsulinemic side 
3 
effects to patients caused by injection. Furthermore, the pain caused by injections 
and the psychological barriers to daily injections such as needle phobia can be 
eliminated via this oral route (Korytkowski, 2002). 
However, there are major hurdles to the effective use of orally delivered insulin. 
These obstacles include the rapid enzymatic degradation of insulin in the stomach, 
inactivation and digestion by proteolytic enzymes in the intestinal lumen, low 
penetration rate of insulin through the gastrointestinal membrane as well as 
biological and structural stability of the insulin in a body system (Timmy et al., 2002; 
Elsayed, 2012). In order to overcome these barriers for successful oral 
administration, many research groups are currently working towards developing new 
oral insulin formulations. These include the attempt to overcome barriers and 
limitations through chemical modification of insulin with various fatty acids (Ashada 
et al., 1995), enzyme inhibitors and penetration enhancers (Liu et al., 2003; Miller & 
Johnston, 2005) and incorporation of insulin into carriers such as hydrogels 
(Nakamura et al., 2014), liposomes (Choudhari & Labhasetwar, 1994), erythrocytes 
(Al-achi & Greenwood, 1998), nanospheres (Damge et al., 1997) and nanocubicles 
(Chung et al., 2004).  
A promising approach used in oral insulin delivery is the encapsulation of 
insulin by cyclodextrin (Zhang et al., 2010; Sajeesh et al., 2010; Uehata et al., 2011; 
Uehata et al., 2012; Zhang et al., 2012; Zhang et al., 2013). The complexations of 
insulin with cyclodextrins offer a unique and effective way to improve the insulin 
properties and stability against aggregation, thermal denaturation and degradation 
(Sigurjonsdottir et al., 1999; Dong et al., 2002). Previously, studies on the 
complexation of insulin with cyclodextrins focused on the interactions of the cationic 
4 
β-CD polymers with insulin (Huang et al., 2010), the insulin cell-penetrating peptide 
co-administrations with hydroxylpropyl-β-CD (Zhang et al., 2010), insulin glargine 
with maltosyl-β-CD (Uehata et al., 2012), insulin encapsulated polymethacrylic acid 
(PMAA) hydrogel microparticles with methyl-β-CD (Sajeesh & Sharma, 2006), 
insulin with hydroxylpropyl-β-CD (Zhang et al., 2009), kinetic degradation of insulin 
complexed with methyl-β-CD (Dotsikas & Loukas, 2002) and β-CD grafting 
hyperbranched polyglycerols as carriers for insulin (Zhang et al., 2011). 
Computer modeling is widely used to understand and predict the properties and 
behaviour of systems at the molecular level. Molecular modeling of insulin using 
molecular dynamics method has been reported. These studies include the dissociation 
of insulin-phenol complex (Kru, 2003), binding of glucose to insulin (Falconi et al., 
2001a; Zoete et al., 2004a), dynamic behaviour of insulin monomer and dimer (Zoete 
et al., 2004b), association of glycoprotein structure with B chain human insulin 
(Stavrakoudis,  2011), insulin stability on graphene (Liang et al., 2009), flexibility of  
B chain human insulin (Legge et al., 2006), structure and stability of insulin dimer 
(Falconi et al., 2001b), insulin interaction with boron-nitride and functionalized 
graphene nanosheets (Atabay et al., 2014), conformational flexibility of insulin 
analogs (Ksenofontova & Stefanov, 2013), simulation of insulin protection by 
trehalose (Li  et al., 2014) and the aggregation and release rate of insulin (Berhanu & 
Masunov,  2012). 
 
 
 
5 
1.2 Problem Statement 
Among the latest development in oral insulin delivery formulation, the 
complexation of insulin with cyclodextrin has been found to be advantageous and 
encouraging. The experimental data on the complexation of insulin with β-CD on 
varying conditions has been investigated in the past few years and support the fact 
that complexation with cyclodextrin improve the stability of insulin. However, it is 
not really understood on how cyclodextrins interact with insulin which may or may 
not lead to insulin conformational change and how these interactions affect the 
thermodynamics and structural properties of insulin upon binding to CD. In order to  
improve our  understanding on the molecular properties insulin-β-CD formation, 
theoretical study comprising of quantum mechanics, molecular docking and 
molecular dynamics simulation was conducted as part of our attempt to understand 
the β-CD behaviour toward insulin monomer and dimer as an oral delivery medium 
for insulin.  
1.3 Objectives 
The objectives of this research are: 
1. To determine the binding sites of β-CDs onto insulin monomer and 
insulin dimer and the best ratios of β-CDs to insulin using molecular 
docking calculation. 
2.       To determine the structural change and stability of insulin monomer and 
insulin dimer following the complexation with β-CDs using molecular 
dynamics simulation. 
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3.       To identify the type of interactions exists between β-CDs and the amino 
acids of insulin involved in the stabilization of the insulin-β-CD 
complexes. 
1.4       Thesis Outline 
This thesis contains five chapters. Chapter 1 provides an overview and the 
background of this study. Chapter 2 reviews the structure, properties of insulin as 
well as cyclodextrins and the previous study on protein-cyclodextrin systems. The 
fundamentals behind computer modeling techniques applied in this study were also 
discussed in this chapter. Chapter 3 describes the methodology for the geometry 
optimization of single insulin monomer and insulin dimer as well as the β-CD 
structure, the multiple molecular docking and finally, the molecular dynamics 
simulation of insulin-β-CD conformations in detail. Chapter 4 contains the results 
and discussion which are divided into three main sections: geometry optimization, 
molecular docking results and molecular dynamics simulation study. Finally, Chapter 
5 summarizes the research findings and further recommendation for possible 
research related to this study. Appendices associated with the relevant documents 
were provided at the end of this thesis.  
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CHAPTER 2 
LITERATURE REVIEW  
2.1 Diabetes and Insulin 
Worldwide, it is expected that over 500 million people will be affected by 
DM in 2030 (Williams et al., 2002). DM causes about 5% of deaths each year (Liu et 
al., 2010) and this is likely to increase by more than 50% in the next 10 years without 
proper medication (http://www.who.int/diabetes/en/). The increasing prevalence of 
diabetes may be due to several factors which are population growth, ageing where an 
increased life expentancy results in a higher ratio of aged population more prone to 
diabetes, urbanisation, increasing obesity, increasing physical inactivity and passive 
lifestyles (Sonia & Sharma, 2014).  
The word ‗Diabetes‘ comes from the Greek work for ‗pipe-like‘ because 
essential nutrients of the body start to pass through the system instead of being 
utilised. Meanwhile „Mellitus‟ is the Latin word for ‗honey‘ or ‗sweet‘ (van Diepen, 
1996). Scientifically, DM is a chronic metabolic disease, which is caused by insulin 
deficiency and an abnormal increase of blood sugar levels in the body (Genuth et al., 
2003). Type 1 DM is most commonly diagnosed in children and adolescents, which 
cannot be prevented and thus occurs when the pancreas does not produce insulin at 
all or only a little. Meanwhile, Type 2 DM occurs when the pancreas produces too 
little glucose. In Type 2 cases, the production of insulin is normal initially, but the 
response activated by insulin in the peripheral tissues is blunted (Alexander & 
Hunter, 2004). When the production of insulin by the pancreas can no longer 
compensate for the peripheral insulin resistance due to β-cell dysfunction, the Type 2 
DM and hyperglycemia become overt. This type of DM usually occurs with 
8 
increasing of age and depends on the lifestyle of the individuals. Type 2 diabetes is 
also found as a component of metabolic syndrome, which is characterised by 
hypertension, central obesity, hyperlipidemia, and insulin resistance that results in 
increased mortality due to cardiovascular incidents. The pervasiveness of both Type 
2 diabetes and metabolic syndrome is reaching epidemic proportions, as the onset 
average age of both diseases has markedly decreased over the past decades (Horton, 
2008).  
Currently, there is no practical cure for diabetes. However, it can be 
controlled effectively through several ways. Lifestyle change involving a modified 
dietary sugar intake and physical exercise (Franz, 1997) should be taken into 
consideration. The oral hypoglycaemic agents are administered to treat diabetic 
patients when diet and exercise are not enough to achieve the desired glycaemic 
control (Krents & Bailey, 2005). There are four classes of hypoglycaemic agents; 
insulin secretagogues (Dunning, 1997), insulin sensitizers (Bailey et al., 1992), α-
glucosidase inhibitors (Gerard et al., 1984) and insulin. Insulin secretagogues, insulin 
sensitizers and α-glucosidase inhibitors are oral medication treatments for 
stimulating endogenous insulin by the pancreas. Meanwhile, insulin is a protein 
therapy needed to be administered exogenously (Sonia & Sharma, 2014).  
As a protein therapy used to treat diabetes, insulin was widely used to 
regulate the level of glucose in the blood system. Approximately 20–30% of all 
diabetic patients receive daily insulin injections in order to maintain their glucose 
levels (Babu et al., 2008). Human insulin is synthesised from beta-cells of the islets 
of Langerhans and is secreted into the bloodstream (Greenspan & Gardner, 2004). It 
plays a crucial role in monitoring the metabolic activities of the body, particularly the 
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homeostasis of the blood glucose. Insulin secretion is a regulated process providing a 
stable concentration of glucose in blood during eating and fasting (Yeh et al., 2010).  
The history of insulin as a protein therapy to diabetes started back to 1922 
when it was first used successfully in humans to treat the symptoms of DM (Bliss, 
1993). The study of diabetes, including the related aspects of glucose metabolism 
was also a fertile ground for scientific inquiry that 10 scientists received the Nobel 
Prize for diabetes-related investigations between 1923 to 2014 as shown in Table 2.1 
(Kim, 2011). In 1958, Frederick Sanger was awarded the Nobel Prize for developing 
techniques to sequence the amino acids of insulin. 
 Rosalyn Yalow in 1960 permitted the quantitative measurement of pancreatic 
beta-cell function in animals and humans and established the radioimmunoassay as a 
powerful tool for measuring proteins, metabolites, and other chemicals present in 
very low concentrations. After that, Donald Steiner‘s in 1967 demonstrated two 
polypeptide insulin molecules were derived from a single chain precursor proinsulin. 
This formation was crucial for the understanding of the biochemistry of insulin and 
was also applied to other peptide hormones. The crystal structure of insulin was then 
determined using 3D crystallography technique by Dorothy Hodgkin in 1969. Insulin 
was the first hormone to be cloned and then produced for therapeutic use by means 
of recombinant DNA technology, while providing an unlimited supply of this 
important molecule and laid down the foundation for the biotechnology industry 
(Ullrich et al., 1977). In the recent development in insulin, Karplus won the Nobel 
Prize for developing multiscale models to describe complex biomolecules. Karplus 
and co-workers successfully developed methods which combined quantum and 
classical mechanics to describe the interaction between glucose and insulin (Zoete et 
al., 2004a).  
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Table 2.1 
Nobel Prizes for Diabetes Related Research (Kim, 2011) 
Year Recipient Contribution 
1923 Banting and Macleod Discovery of insulin 
1947 Cori and Cori Discovery of the course of the 
catalytic conversion of glycogen 
1947 Houssay Discovery of the role of hormones 
released by the anterior pituitary lobe 
in the metabolism of sugar 
1958 Sanger Discovery of the protein structures 
including insulin 
1960 Yalow Development of radioimmunoassays 
for peptide hormones 
 
1969 Hodgkin Discovery of insulin crystal structure 
using 3D crystallography technique 
1971 Sutherland Discovery of the mechanisms of 
action of hormones 
1992 Fischer and Krebs Discovery of reversible protein 
phosphorylation as a biologic 
regulatory mechanism 
  2014 Karplus Development of multiscale models for 
complex chemical systems including 
insulin 
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2.1.1 Structure of Insulin 
Insulin is synthesised in beta cells of the pancreas where the messenger RNA 
(mRNA) is translated as a single chain precursor named preproinsulin (Dodson & 
Steiner, 1998). The removal of preproinsulin‘s signal peptide during insertion into 
the endoplasmic reticulum (ER) generates proinsulin. After that, the proinsulin folds 
into a three-dimensional structure, whereby it is transported with the help of vesicles 
to Golgi. In this medium, proinsulin is likely self-assembles to form proinsulin 
hexamers, in which connecting peptide linking A and B chain, then is cleaved by 
enzymes. This promotes towards the formation of zinc assembled of insulin hexamer, 
which are capable of forming microcrystals. Finally, hexamers will fall apart into 
insulin monomers due to repulsion in certain charged residues at its core (Vashisth, 
2010). The final formation of insulin is in monomeric form which is used to stabilise 
glucose concentrations in living system. 
Insulin monomer is a small globular protein composed of two polypeptide 
chains. A Chain consists of the sequence of 21 amino acids, whereas B chain consists 
of 30 amino acids. Both chains were stabilised by three disuplhide bonds, whereby, 
two disulphide bridges between A chain and B chain were formed between the 
residues Cystein7 (Cys7) to Cystein28 (Cys28) and Cystein20 (Cys20) to Cystein40 
(Cys40). The other disuphilde bridge was internally formed between residues 
Cystein6 (Cys6) to Cystein11 (Cys11) in A chain of insulin monomer. Generally, A 
chain contains N-terminal α-helix, turn conformations, whereas the B-chain contains 
N-terminal and central α-helix, and C-terminal β-strand (Olsen et al., 1996). At 
micromolar concentration, the insulin dimerises and further forms hexamers in the 
presence of zinc and phenolic species as shown in Figure 2.1.   
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(a)                                    (b) 
                                     
Figure 2.1. Structures of insulin (a) monomer (b) dimer. 
Chain A 
Chain B 
Chain B’ 
Chain A 
Chain B 
Chain A’ 
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The insulin dimer was formed when the extended C-terminal of two 
monomers are brought together, thus, forming a two-stranded antiparallel β-sheet. 
The interactions stabilizing the dimer form of insulin are predominantly non-polar 
with β-sheet hydrogen bonds replacing water hydrogen bonds and contributing to 
orientate two monomers (Jorgensen et al., 1996). The published high resolution X-
ray structures of insulin suggested as the aggregated species at which several reports 
provide the results for monomeric form of insulin (Zhang et al., 2002). Therefore, the 
current insulin structure was derived from insulin hexamer and dimer crystal 
structures.  
Biologically, insulin monomer is active and capable of self-association 
forming dimers and hexamers in biosynthesis and during storage of insulin (Dodson 
& Steiner, 1998). Insulin monomer is unstable compared to dimer and hexamers and 
is therefore the main reason why many researchers used the dimer form.  In addition, 
insulin monomer forms aggregates and fibrils due to the interactions between the 
hydrophobic residues in the monomer and this behaviour are often associated with 
the reduction of biological potency of insulin monomer (Dunn, 2005).  Insulin dimer 
and hexamer are also known to be more resistant to chemical and physical 
degradation than its monomer form (Loftsson et al., 2005). Insulin monomer with A 
and B chains comprises of Gly1  Ala51, while, insulin dimer is made up of two 
monomers with chains A, B, A‘ and B‘ consists of Gly1  Ala102 as shown in the 
numbering structure of insulin in Figure 2.2. 
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Figure 2.2. The numbering scheme for insulin dimer, which comprises of monomers I and II. Blue lines represent the disuplhide bridges.
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2.1.2 Development of Insulin Delivery 
The most crucial treatment strategy for DM focuses on the control of 
postprandial blood glucose. Therefore, the goal of exogenous insulin is to mimic the 
physiological profile in a non-diabetic person. In the past few decades, various routes 
of insulin administration were explored in order to discover a new technique of 
insulin administrations that will improve the metabolic effects of insulin. The current 
administration of insulin which is via subcutaneous route has various disadvantages, 
such as injection site pain, low patient compliance, and occasional hypoglycemia 
(Khafagy et al., 2007). Furthermore, insulin administration via subcutaneous 
injection does not mirror the normal dynamics of endogenous insulin release, 
promoting in failure to achieve lasting glycemic control (Hoffman & Ziv, 1997; 
Morishita et al., 2006). Various routes other than subcutaneous, which under 
investigation for insulin delivery include oral (Huang et al., 2009; Zhang et al., 
2013), pulmonary (Mastrandrea, 2010), transdermal (Krishnankutty et al., 2009), 
nasal (Turker et al., 2004), buccal (Senel & Hincal, 2001), ocular (Lee et al., 2002), 
rectal (Ritschel et al., 1988) and vaginal (Choudhury et al., 2011). Among all the 
possible routes, oral insulin delivery serves as the most expedient and desired way of 
insulin administration due to patient compliance and comfort. Furthermore, an oral 
pathway of insulin delivery is expected to follow the physiological route of insulin 
secretion (Lewis et al., 1996), which is accompanied by greater hepatic versus 
peripheral concentrations (Gordon-Still, 2002).  
There are a few other major hurdles to develop oral insulin delivery, such as 
the presence of chemical and enzymatic barrier in the gastrointestinal tract that could 
degrade the insulin structure (Sonia & Sharma, 2014), the poor permeation of insulin
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across the intestinal epithelia (Muller, 2011), with low bioavailability (typically less 
than 1–2%) (Renukuntla et al., 2013), and stability of insulin which depend on a few 
factors such as temperature, pH, solvent, solutes and crystallinity states of the insulin 
(Manning et al., 1989). One of other major barrier in order to develop oral delivery 
insulin is poor of insulin absorption through the gastrointestinal membrane (Carino & 
Mathiowitz, 1999). The high molecular weight of insulin, which is about 6 kDa 
could not also penetrate through this route.  The insulin absorption is prevented due 
to its large molecule size, charge and hydrophilicity (Elsayed, 2012). Oral delivery of 
insulin for DM was tried in diabetic induced rats by Roques and co-workers (1992) 
who reported one of the major problems is degradation of the insulin due to 
proteolytic activity of enzymes in the gastrointestinal tract.  
A perfect oral drug delivery system should be capable of maintaining the 
purity of insulin molecules until it reaches the absorption site, releasing insulin at the 
targeted absorption site and maintaining inside the gastrointestinal tract irrespective 
of its transitory constraints (Renukuntla et al., 2013). The crucial parts of oral 
delivery insulin should be safe delivery to human body, increased in bioavailability 
as well as enhanced insulin absorption. Many research groups focused on 
development of a delivery system for insulin oral administration using absorption 
enhancers (Onuki et al., 2000; Thanou et al., 2000), enzyme inhibitor (Agarwal et al., 
2000), enteric coatings (Hosny et al., 2002) and nanoparticle delivery (Ezpeleta et al., 
1999). The permeation of nanoparticles still results in poor bioavailability of the 
insulin. The use of protease inhibitors in addition to absorption enhancers leads to 
improved uptake insulin. Nonetheless, these agents are not specific and could assist 
in the uptake of other unwanted protein or peptides in the gastrointestinal tract 
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(Nakamura et al., 2014). Some promising results were also obtained, indicating 
clearly that oral administration of insulin mimicking the physiological fate of insulin. 
However, most production techniques involve the use of organic solvents, heat or 
vigorous agitation potentially harmful to the structure as well as the biological 
activity of insulin and were lead to problems of cytotoxicity (Khafagy et al., 2007). 
These limitations could be effectively overcomed by insulin encapsulation agent 
such as β-CD and derivatives (Ahsan et al., 2003; Sajeesh et al., 2010; Zhang et al., 
2012). 
2.2 Cyclodextrins      
2.2.1 Structures and Properties of α-, β- and γ-CDs 
Cyclodextrins (CDs) are cyclic oligosaccharides linked through α-1, 4-
glycosidic bonds which composed of 6, 7 or 8 glucose units classified as α-, β-, and 
γ-CDs, respectively, as shown in Figure 2.3. CDs are produced from enzymatic 
digestion of starch by CD glycosyltransferase (CGTase) isolated from Bacillus 
maceranc (French, 1957). Due to advancement of biotechnology in recent decades, 
highly purified CD and CD derivatives were widely produced in large scale 
(Loftsson & Duchene, 2007). 
 
Figure 2.3. Structures of α-, β- and γ-CDs (Szejtli, 1998). 
α-CD 
β-CD 
γ-CD 
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Each of the chiral glucose units in CD is in the 
4
C1 chair conformation of the 
sugar units, providing a hollow truncated cone shape where hydroxyl groups are 
oriented to the exterior, while skeletal carbon and ethereal oxygen moieties are 
oriented to the central cavity (Brewster & Loftsson, 2007). The C-2-OH group of one 
glucopyranose unit can form a hydrogen bond with the C-3-OH group of the adjacent 
glucopyranose unit. A complete secondary belt is formed by this hydrogen bonding 
formation, thus providing a rigid CD structure. The interior cavity of CD is 
hydrophobic, while the exterior site is hydrophilic in nature (Connors, 1997) as 
shown in a schematic view in Figure 2.4.  
 
 
 
 
 
 
 
 
 
 
Figure 2.4. The hollow truncated cone structure of CD. 
 
The cavity size of α-CD is the smallest of the three CDs while γ-CD has the 
largest cavity size of all three CDs and is the most expensive too. Therefore, β-CD is 
 
 
                            
 
Secondary hydroxyls 
Primary hydroxyls 
Hydrophobic cavity 
Hydrophilic exterior 
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most widely used in research and manufacturing due to its cost and suitable cavity 
size for most compound molecules (Loftsson & Brewster, 1996; Szejtli, 1998).  
Cyclodextrins are soluble in water and insoluble in most organics solvents 
although β-CD is the least soluble in water compare to the other native CDs. The 
solubility of cyclodextrins in water is unusual and does not seem to be dependent on 
the structure of cyclodextrin (Sabadini et al., 2006). α-CD is the most strained torus 
structure while γ-CD ring is the least strained among the three native cyclodextrins. 
β-CD is 9 and 11 times less soluble in water in comparison to α-CD and γ-CD, 
respectively. Table 2.2 summarizes the size and the properties of native CDs (Szejtli, 
1998). 
Table 2.2 
Physicochemical Properties of α-, β- and γ-CDs 
Properties/CD α-CD β-CD γ-CD 
Number of glucose units 6 7 8 
Molecular weight 972 1135 1297 
Solubility in H2O (g/mL) 14.50 1.85 23.20 
pKa 12.33 12.20 12.08 
Inner diameter (Å) 4.70-5.30 6.00-6.50 7.50-8.30 
Outer diameter (Å) 14.60 ± 0.4 15.40 ± 0.4 17.50 ± 0.4 
Height (Å) 7.90 ± 0.1 7.90 ± 0.1 7.90 ± 0.1 
Cavity volume (Å
 3
) 174 262 427 
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According to the report summarized by Szejtli (1998), CDs are mostly 
nontoxic. One of the few toxicities of CD reported is hemolysis, which is a 
phenomenon resulted from interactions of CD with membrane components (Szejtli, 
1988; Shen et al., 1998). It is reported that lower concentration of CD protects the 
human erythrocytes against osmotic and heat-induced hemolysis. CD is known to 
cause the release of cholesterol and phospholipids from cell membrane thus resulting 
in cell disruption (Uekama et al., 1981; Shen et al., 1998). 
Apart from that, the nonbonding electron pairs of the glycosidic oxygen 
bridges of β-CDs are directed toward the inside of the cavity producing high electron 
density and also lending on some Lewis base characteristics which is important for 
their capability to form host-guest complexes (Szejtli, 1998). 
2.2.2 Applications of CDs 
The modification of compounds with CDs lead to a large number of 
applications in various fields related to pharmaceutical industry, food technology, 
analytical chemistry, chemical synthesis and catalyst (Saenger, 1980; Szejtli, 1988; 
Wilsom & Verall, 1998) as illustrated in Figure 2.5.  
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Figure 2.5. Distribution of the CD relevant abstracts published by Cyclodextrin 
News (Cyclodextrin News, 1996). 
 
CDs provide many beneficial improvements to products including solubility 
and stabilisation of the guest compound which provide long-term protection of 
colour, odour and flavour of products. Besides, the nontoxicity of CD is also the 
main reason for its application in the pharmaceutical and food industry (Omari et al., 
2010; Misiuk & Zalewska, 2011) with more than 40 formulations containing CDs on 
the market currently, intended for oral, parenteral, ophthalmic, rectal and dermal 
route of application (Gidwani & Vyas, 2015). Barone et al. (1998) and Nasongkla et 
al. (2003) reported that β-CD was used to increase bioavailability of poorly soluble 
drugs. Light, thermal and oxidative stability of drug molecules can also be improved 
through the formation of cyclodextrin complexes (Cwiertnia et al., 1999; Tirucherai 
& Mitra, 2003). Other pharmaceutical application of CDs is to reduce dermal 
(Uekama et al., 1992), ocular irritation (Loftsson & Stefansson, 1997) and to avoid 
adverse drug-ingredient interactions (Redenti et al., 2001). 
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One of the uses of CD in the cosmetic industry is in the production of long-
lasting fragrances (Schmid, 1989) and reducing body odours (Trinh et al., 1999). 
Other applications include its use in toothpaste, skin creams, liquid and solid fabric 
softeners, paper towels and tissues (Szejtli, 1998) that contributed to 7.09 % of total 
use of CDs. In the food industry, β-CD was used to remove cholesterol from 
products such as milk, butter and eggs (Singh et al., 2010; Kemelbekov et al., 2011).  
Furthermore, the applications of CDs in agricultural fields include in the production 
of insecticides, fungicides and herbicides to improve plant growth and increase 
harvest yield. Other than that, CDs can also be used in many chromatographic 
techniques for separation of enantiomers (Szejtli, 1998). Table 2.3 summarises the 
applications of CDs in various sectors. 
 
Table 2.3 
The Summary Applications of CDs (Valle, 2003) 
Sector Applications 
Cosmetic, personal care and toiletry  Production of toothpaste, skin creams, 
paper towel, liquid and solid fabric 
softener, tissues, underarms shields, 
dishwashing and laundry detergent, 
talcum powder, sunscreen lotions. 
Foods and flavours 
 
 
 
 
 
 
 Removing cholestrols from milk, 
butter and eggs. 
 Improving texture on meat and pastry 
products. 
 Protecting the flavour throughout 
many rigorous food-processing 
methods of freezing, thawing and 
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microwaving. 
 Production of dairy products with low 
cholestrols. 
  Improving elasticity in noodles, pie, 
dough and pizza.  
 Act as the antimicrobial food 
preservatives. 
Pharmaceuticals  Production of mouthwash solution, 
nasal drug, eye drop solution. 
 Reducing the effects of bitter or 
irritant tasting and bad smelling drugs. 
Agriculture and chemical industries  Production of herbicides, insecticides, 
fungicides, repellents, pheromones. 
 Use in separation of isomers and 
enantiomers.  
 Removing or detoxifying waste 
materials. 
Adhesives, coating and polymers  Increasing tackiness and adhesion of 
hot melts and adhesive.  
 
 
2.2.3 Mechanism of Protein-CDs Interaction 
Interactions between CD and protein have also given surprising outcomes as 
CDs were employed as catalyst to alter some properties of protein (Hamilton et al., 
2000; Mcgarraghy & Darcy, 2000) and is in the improvement on protein solubility, 
which could lead to the protein stabilisation in water (Koralewska et al., 2004). This 
happened as the hydrophobic cavity of CDs is capable to provide temporary asylum 
for hydrophobic parts of protein molecules to dissolve in water. The solubilisation 
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ability of CDs is currently of interest in the development of many formulations to 
improve the bioavailability of protein system (Duchene, 1991). 
Furthermore, the interactions of CDs with hydrophobic groups on protein 
molecules can reduce protein aggregation. This phenomenon was observed in the 
dissociation of bovine insulin dimers in the presence of different CDs (Lovatt et al., 
1996). The inhibition of protein aggregation also occurred to bovine insulin 
(Dotsikas & Loukas, 2002), recombinant human growth hormone (rh-Gh) (Otzen et 
al., 2002) and several other proteins (Sharma & Sharma, 2001; Sigurjonsdottir et al., 
1999). The study of Tavornvipas and co-workers (2004) showed the relationship 
between reduction of aggregation and binding constants of CD-derivatives and rh-
GH. In their study, the branched CDs turned out to be the most competent in the 
prevention of protein unfolding and aggregation. The same CDs have been also 
reported to produce the highest stability constants among other CDs. Other findings 
involving the interaction between CD and protein include the binding mechanism 
between aripiprazole (APZ) with human serum albumin (HSA) in the presence of 
three types of CDs (Yan et al., 2015). The study reported the refolding recovery of 
APZ and HSA caused by CD which is specifically involved the interaction between 
HSA and CD. Current studies on the interaction between CD and protein such as 
phenylalanine dehydrogenase enzyme (Gubica et al., 2015) and mithochondrial 
ADP/ATP carrier (AAC) (Rather et al., 2015) have also been reported. 
Nonetheless, proteins such as insulin are mostly hydrophilic and too bulky to 
be wholly encapsulated into the β-CD cavity. According to Irie and Uekama (1999) 
the hydrophobic side chains of insulin peptides penetrate into the β-CD cavity 
leading to the formation of non-covalent inclusion complexes. The CDs‘ ability to 
